Evidence map›Paper›PMID 34697184›Full record

ArticleIn vivo (Athens, Greece)

The Clinical Influence of the C-Reactive Protein-to-Albumin Ratio in Patients Who Received Curative Treatment for Gastric Cancer.

Toru Aoyama, Masato Nakazono, Kenki Segami, Shinsuke Nagasawa, Kazuki Kano, Takanobu Yamada, Yukio Maezawa, Kentaro Hara, Itaru Hashimoto, Hideaki Suematsu and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Toru AoyamaDepartment of Surgery, Yokohama City University, Yokohama, Japan; t-aoyama@lilac.plala.or.jp oshimat@kcch.jp.
Masato NakazonoDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Kenki SegamiDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Shinsuke NagasawaDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Kazuki KanoDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Takanobu YamadaDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Yukio MaezawaDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Kentaro HaraDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Itaru HashimotoDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Hideaki SuematsuDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Hayato WatanabeDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Kosuke TakahashiDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Masakatsu NumataDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Hiroshi TamagawaDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Norio YukawaDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Yasushi RinoDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Takashi OgataDepartment of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.
Takashi OshimaDepartment of Surgery, Yokohama City University, Yokohama, Japan; t-aoyama@lilac.plala.or.jp oshimat@kcch.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe investigated the impact of the pre-surgical C-reactive protein-to-albumin ratio (CAR) on survival and recurrence after curative treatment for gastric cancer. PATIENTS AND

methodsThis study included 481 patients who underwent curative treatment for gastric cancer between 2013 and 2017. The risk factors for overall (OS) and recurrence-free (RFS) survival were identified.

resultsA CAR of 0.05 was regarded as the optimal critical point of classification considering the 3- and 5-year survival rates and patients were divided according to their CAR. The OS rates at 3 and 5 years after surgery were significantly higher at 92.5% and 87.9%, respectively, in the low-CAR group compared with 84.9% and 71.9%, respectively, in the high-CAR group. The corresponding RFS rates were 89.1% and 85.5%, and 81.0% and 72.2%, respectively, also a significant difference. A multivariate analysis demonstrated that the CAR was a significant independent risk factor for the OS and marginally significant independent risk factor for the RFS. In addition, the incidences of pancreatic fistula and abdominal abscess were significantly higher and the rate of introduction of adjuvant chemotherapy significantly lower in the high-CAR group.

conclusionThe CAR was a risk factor influencing survival in patients who underwent curative treatment for gastric cancer. An effective perioperative care plan and surgical strategy need to be developed according to the CAR.

Indexed as

C-Reactive ProteinStomach NeoplasmsHumansNeoplasm Recurrence, LocalPrognosisRetrospective StudiesC-Reactive ProteinalbuminC-reactive proteinGastric cancersurvival

Identifiers

PMID34697184
PMCPMC8627710

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.